Retroperitoneal unicentric Castleman’s disease: A multidisciplinary approach in a rare case
Keywords:
retroperitoneal mass, Castleman's diseaseAbstract
Retroperitoneal masses, presents with various clinical forms, are very difficult to diagnose before surgery. Castleman's Disease occurs in the lymphoid chain and is characterized by angiofollicular hyperplasia of the lymphoid tissue with an unknown etiology. In this case report, we will share with venerable readers a rare occurrence of retroperitoneal Castleman's Disease in the light of the current literature.
References
1. Mohagheghi M, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F et al. A case of advanced unicentric retroperitoneal castleman's disease, associated with psoriasis. Acta Medica Iranica, 2017; 55(4):277-279.
2. Sbrana F, Zhou D, Zamfırova I, Leonardi N. Castleman’s disease: a rare presentation in a retroperitoneal accessory spleen, treated with a minimally invasive robotic approach. Journal of Surgical Case Reports, 2017; 10:1-3.
3. Abdessayed N, Bdioui A, Ammar H, Gupta R, Mhamdi N, Guerfela M et al. Retroperitoneal unicentric castleman’s disease: a case report. International Journal of Surgery Case Reports, 2017; 31;54-57.
4. Castleman B, Iverson L, Menendez P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer, 1956; 9:822–830.
5. Williams A, Sanchez A, Hou J, Rubin R, Hysell M, Babcock B et al. Retroperitoneal castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity. World Journal of Surgıcal Oncology, 2014; 12:30.
6.Bowne B, Lewis J, Filippa D, Niesvizky R, Brooks A, Burt M et al. The management of unicentric and multicentriccasleman’s disease, 1999; 85(3):706-717.
7. Bucher P, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal castleman’s disease. World Journal of Surgical Oncology, 2005; 3:33
8. Özden C, Han Ö, Atagün D, Güzel Ö, Seçkin S, Memiş A. Paraüreteral ve pararenal castleman’s hastalığı: olgu sunumu. Turkish Journal of Urology, 2007; 33(1):114-116.
9. Casper C. The aetiology and manahement of castleman disease at 50 years: translating pathophysiology to patient care. British Journal of Haematology, 2005; 129:3-17.
10. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric castleman disease. Blood Journal, 2005; 106(8):2627-2632.
11. Dupin N, Diss T, Kellam P, Tulliez M, Du M, Sicard D et al. HHV-8 is associated with a plasmablastic variant of castleman disease that is linked to HHV-8 positive plasmablastic lymphoma. Blood Journal, 2000; 95(4):1406-1412.
12. Nishi J, Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in casleman’s disease: proposed pathomechanism of vascular proliferation in the affected lymph node. Leukemia and Lymphoma, 2000; 38(3-4):387-394.
13. Ocio E, Sanchez-Guijo F, Diez-Campelo M, Castilla C, Blanco O, Caballero D et al. Efficacy of rituximab in an aggressive form of multicentric castleman disease associated with immune phenomena. American Journal of Hematology, 2005; 78:302-305.
2. Sbrana F, Zhou D, Zamfırova I, Leonardi N. Castleman’s disease: a rare presentation in a retroperitoneal accessory spleen, treated with a minimally invasive robotic approach. Journal of Surgical Case Reports, 2017; 10:1-3.
3. Abdessayed N, Bdioui A, Ammar H, Gupta R, Mhamdi N, Guerfela M et al. Retroperitoneal unicentric castleman’s disease: a case report. International Journal of Surgery Case Reports, 2017; 31;54-57.
4. Castleman B, Iverson L, Menendez P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer, 1956; 9:822–830.
5. Williams A, Sanchez A, Hou J, Rubin R, Hysell M, Babcock B et al. Retroperitoneal castleman’s disease: advocating a multidisciplinary approach for a rare clinical entity. World Journal of Surgıcal Oncology, 2014; 12:30.
6.Bowne B, Lewis J, Filippa D, Niesvizky R, Brooks A, Burt M et al. The management of unicentric and multicentriccasleman’s disease, 1999; 85(3):706-717.
7. Bucher P, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal castleman’s disease. World Journal of Surgical Oncology, 2005; 3:33
8. Özden C, Han Ö, Atagün D, Güzel Ö, Seçkin S, Memiş A. Paraüreteral ve pararenal castleman’s hastalığı: olgu sunumu. Turkish Journal of Urology, 2007; 33(1):114-116.
9. Casper C. The aetiology and manahement of castleman disease at 50 years: translating pathophysiology to patient care. British Journal of Haematology, 2005; 129:3-17.
10. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric castleman disease. Blood Journal, 2005; 106(8):2627-2632.
11. Dupin N, Diss T, Kellam P, Tulliez M, Du M, Sicard D et al. HHV-8 is associated with a plasmablastic variant of castleman disease that is linked to HHV-8 positive plasmablastic lymphoma. Blood Journal, 2000; 95(4):1406-1412.
12. Nishi J, Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in casleman’s disease: proposed pathomechanism of vascular proliferation in the affected lymph node. Leukemia and Lymphoma, 2000; 38(3-4):387-394.
13. Ocio E, Sanchez-Guijo F, Diez-Campelo M, Castilla C, Blanco O, Caballero D et al. Efficacy of rituximab in an aggressive form of multicentric castleman disease associated with immune phenomena. American Journal of Hematology, 2005; 78:302-305.
Downloads
Published
2018-12-05
How to Cite
Asfuroglu, A., Balci, M., Aslan, Y., Guzel, O., Albayrak, A., & Tuncel, A. (2018). Retroperitoneal unicentric Castleman’s disease: A multidisciplinary approach in a rare case. Insight Urology, 39(2), 50–55. Retrieved from https://he02.tci-thaijo.org/index.php/TJU/article/view/118796
Issue
Section
Case Report
